Althexis Co. Inc. operates on the idea that shrewd selection of targets combined with a bottleneck-breaking assay technology will enable the company to achieve new levels of efficiency in structure-based drug design.

Founded by scientists from Vertex Pharmaceuticals Inc. (VRTX, Cambridge, Mass.), Althexis has developed a technology designed to get around the well known difficulty of producing high throughput assays for use in compound screening against targets of unknown function. But the company believes that its quest for efficiency ultimately will be realized by applying the technology to targets that offer higher probabilities of success.